Ohsfeldt RL， Gandhi SK， Smolen LJ， Jensen MM， Fox KM， Gold A， Hsia J.
    Texas A&M Health Science Center， College Station， TX， USA.
Abstract
    Abstract Objective: This study assessed the long-term cost effectiveness of rosuvastatin therapy compared with placebo in reducing the incidence of major cardiovascular (CVD) events and mortality.

    Methods: A probabilistic Monte Carlo simulation model estimated long-term cost effectiveness of rosuvastatin therapy (20 mg daily) for the prevention of CVD mortality and morbidity. The model included three stages: (1) CVD prevention simulating the 4 years of the JUPITER trial， (2) initial CVD prevention beyond the trial， and (3) subsequent CVD event prevention. A US payer perspective was assessed reflecting direct medical costs， and up to a lifetime horizon. Sensitivity analyses tested the robustness of the model estimates.

    Results: For a hypothetical cohort of 100，000 patients at moderate and high risk of CVD events based on Framingham risk of ≥10%， estimated quality-adjusted life-years (QALYs) gained with rosuvastatin therapy compared with placebo was 33，480 over a lifetime horizon， and 25，380 and 9916 over 20-year and 10-year horizons， respectively. Approximately 12，073 events were avoided over the lifetime; 6，146 non-fatal MIs， 2905 non-fatal strokes， and 4030 CVD deaths avoided. Estimated incremental cost-effectiveness ratio (ICER) for cost per QALY was